Enfortumab Biosimilar Antibody-Drug Conjugate (Nectin-4) for Research

Cat No.: GMP-Bios-ab-182

Pre-Made Enfortumab biosimilar, Whole mAb ADC, Anti-PVRL4/NECTIN4 Antibody: Anti-EDSS1/LNIR/PRR4/nectin-4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enfortumab vedotin,[1] sold under the brand name Padcev, is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-182-1mg 1mg 4635
GMP-Bios-ab-182-10mg 10mg
GMP-Bios-ab-182-100mg 100mg
GMP-Bios-ab-182-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Enfortumab biosimilar, Whole mAb ADC, Anti-PVRL4/NECTIN4 Antibody: Anti-EDSS1/LNIR/PRR4/nectin-4 therapeutic antibody
INN Name Enfortumab
TargetNECTIN4
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesAgensys;Seattle Genetics
Conditions Approvedna
Conditions ActiveUrogenital cancer
Conditions Discontinuedna
Development Techna



About target - PVRL4

1. Protein Nectin-4

2. Gene PVRL4

3. Organism Homo sapiens (Human)

Function
Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.
(Microbial infection) Acts as a receptor for measles virus.